FDA product code · General hospital
Subcutaneous Implanted Apheresis Port
3 FDA decisions since 2017. No recall names this code. The most-cited predicate is K163001, named by 2 later devices.
A subcutaneous implanted apheresis port is a prescription device intended for patient therapies requiring repeated access to the vascular system and long-term therapeutic apheresis
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly Download the data (CSV)
Twenty years of PTD at a glance: how often FDA decides these devices, how long 510(k) reviews take, how often they are recalled, and how many adverse event reports name the code.
FDA decisions per year · PTD
1in 2020
2026 to Oct 25, outlined.
Median 510(k) review, days · PTD
Too few PTD 510(k)s in any year since 2007 to give a median.
Recalls per year · PTD
No recall names PTD since 2007.
Adverse event reports per year · PTD
26in 2025
MAUDE reports naming product code PTD, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 0 | — | 0 | 0 |
| 2008 | 0 | — | 0 | 0 |
| 2009 | 0 | — | 0 | 0 |
| 2010 | 0 | — | 0 | 0 |
| 2011 | 0 | — | 0 | 0 |
| 2012 | 0 | — | 0 | 0 |
| 2013 | 0 | — | 0 | 0 |
| 2014 | 0 | — | 0 | 0 |
| 2015 | 0 | — | 0 | 0 |
| 2016 | 0 | — | 0 | 0 |
| 2017 | 1 | — | 0 | 4 |
| 2018 | 0 | — | 0 | 15 |
| 2019 | 1 | — | 0 | 35 |
| 2020 | 1 | — | 0 | 18 |
| 2021 | 0 | — | 0 | 15 |
| 2022 | 0 | — | 0 | 11 |
| 2023 | 0 | — | 0 | 25 |
| 2024 | 0 | — | 0 | 22 |
| 2025 | 0 | — | 0 | 26 |
| 2026 | 0 | — | 0 | — |
Planning a device in PTD? A 510(k) Report ranks candidate predicates in this code by lineage, citations and recall history, with the review-time outlook.
See the 510(k) ReportRelated product codes
Other codes under 21 CFR 880.5965.